Details:

Alternative Title:
Vaccine
Personal Author:
McMorrow, Meredith L. ; Tempia, Stefano ; Walaza, Sibongile ; Treurnicht, Florette K. ; Ramkrishna, Wayne ; ... More +
McMorrow, Meredith L. ; Tempia, Stefano ; Walaza, Sibongile ; Treurnicht, Florette K. ; Ramkrishna, Wayne ; Azziz-Baumgartner, Eduardo ; Madhi, Shabir A. ; Cohen, Cheryl Less -
Description:
Background:

Due to competing health priorities, low- and middle-income countries (LMIC) may need to prioritize between different influenza vaccine risk groups. Risk group prioritization may differ in LMIC based upon programmatic feasibility, country-specific prevalence of risk conditions and influenza-associated morbidity and mortality.

Methods:

In South Africa, we collected local disease burden data (both published and unpublished) and published vaccine efficacy data in risk groups and healthy adults. We used these data to aid policy makers with risk group prioritization for influenza vaccination. We used the following formula to assess potential vaccine averted disease in each risk group: rate of influenza-associated hospitalization (or death) per 100,000 population * influenza vaccine efficacy (VE). We further estimated the cost per hospital day averted and the cost per year of life saved by influenza vaccination.

Results:

Pregnant women, HIV-infected adults, and adults and children with tuberculosis disease had among the highest estimates of hospitalizations averted per 100,000 vaccinated and adults aged 65 years and older had the highest estimated deaths averted per 100,000 vaccinated. However, when assessing both the cost per hospital day averted (range: USD148–1,344) and the cost per year of life saved (range: USD112–1,230); adults and children with TB disease, HIV-infected adults and pregnant women had the lowest cost per outcome averted.

Discussion:

An assessment of the potential disease outcomes averted and associated costs may aid policymakers in risk group prioritization for influenza vaccination.


Subjects:
[+]
Adolescent Adult Aged Article Case-Control Studies Child Child, Preschool Cost-Benefit Analysis Cost Of Illness Female Health Priorities Health Resources HIV Infections/epidemiology Hospitalization Hospitalization/economics Humans Infant Influenza, Human/mortality Influenza, Human/prevention & Control Influenza Vaccines/economics Influenza Vaccines/therapeutic Use Male Middle Aged Pregnancy Risk Factors Tuberculosis/epidemiology Vaccination/economics Young Adult
Source:
Vaccine. 37(1):25-33
Pubmed ID:
30471956
Pubmed Central ID:
PMC6470296
Document Type:
Journal Article
Funding:
CC999999/Intramural CDC HHS/United States ; U01 IP001048/IP/NCIRD CDC HHS/United States
CC999999/Intramural CDC HHS/United States ; U01 IP001048/IP/NCIRD CDC HHS/United States Less -
Place as Subject:
South Africa
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:6a66fdc0190827efd9ff7f55deca1b887df54cc37d6a6e4c929f299b85465155
Download URL:
https://stacks.cdc.gov/view/cdc/77654/cdc_77654_DS1.pdf
File Type:

Supporting Files

• 	nihms-1012564.nxml	xml
  	NIHMS1012564-supplement-2.docx	docx

More +